Previous literature has shown that hemodialysis patients have impaired dietary intakes on dialysis days (DDs), which may contribute to malnutrition and poor outcomes. In this study, we examined dietary intakes of 140 hemodialysis patients based on 3 nonconsecutive days food records (collected on 1 DD and 2 non-DDs). Patients had lower energy intake and other key nutrient intake on DDs; however, upon adjusting for energy intake, nutrient differences were no longer significant. None of the patient characteristics examined were associated with impaired intakes on DDs (P > .05).
Center for Healthful Behavior Change, Department of Population Health, New York University School of Medicine (Mss Mirza, Shahsavarian, and Pompeii and Drs St-Jules and Sevick); and Harold Simmons Center for Chronic Disease Research and Epidemiology, University of California Irvine School of Medicine (Drs Rhee and Kalantar-Zadeh).
Correspondence: David E. St-Jules, PhD, RD, Center for Healthful Behavior Change, Department of Population Health, New York University School of Medicine, 550 1st Ave, New York, NY 10016 (email@example.com).
The authors thank the management and staff of the participating dialysis units from DaVita HealthCare Partners Inc., Dialysis Clinic Inc., and Fresenius Medical Care North America; research study dietitians Beth Hall, BA, RD, LDN, and Susan Stark, MS, RD, CSR, LDN, for conducting the interventions; Deborah Klinvex, BA, for conducting the dietary recall interviews; D. Scott Obrosky, MS, for developing the data-tracking system; and Tienna Luster for data management.
The BalanceWise study was supported by the following National Institutes of Health (NIH) grants: NINR/R01-NR010135 & NINR/NIDDK/NHLBI/NIA-K24-NR012226. NIH played no role in study design; collection, analysis, and interpretation of data; writing the report; or the decision to submit the report for publication. Dr K. Kalantar-Zadeh has received commercial honoraria and/or support from Abbott, Abbvie, Alexion, Amgen, Astra-Zeneca, Aveo, Chugai, DaVita, Fresenius, Genentech, Haymarket Media, Hospira, Kabi, Keryx, Novartis, Pfizer, Relypsa, Resverlogix, Sandoz, Sanofi, Shire, Vifor, UpToDate, and ZS-Pharma. [US government agencies (such as NIH) and not-for-profit foundations or societies (such as NKF) are not listed, while Dr Kalantar has also received additional honoraria from such entities].
The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article.